TMCnet News

Research and Markets: The Total Value of Drugs on Chinese Healthcare Market to be More than 1450 Billion RMB By 2015
[March 18, 2014]

Research and Markets: The Total Value of Drugs on Chinese Healthcare Market to be More than 1450 Billion RMB By 2015


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/3vqhjh/chinese_guidebook) has announced the addition of the "Chinese Guidebook for Adverse Drug Reaction Reporting and Monitoring Regulations (2014)" report to their offering.

China is one of the fastest growing global economies with a fifth population in the world, and is one of the largest healthcare markets around the world. Along with sustained economic and population growth, Chinese healthcare market has maintained annually average growth rate above 16 % since 1990s. By 2013, total value of drugs on Chinese healthcare market has reached RMB 1114 billion.

On the Chinese healthcare market, imported drugs made by overseas and multinational pharmaceutical manufactures account for about one fourth. It is estimated that total value of drugs on Chinese healthcare market will be likely to be more than 1450 billion RMB by 2015, and will surpass Japan to become the second largest drug market following the United States. The Chinese healthcare market will attract more and more overseas pharmaceutical manufacturers and producers to penetrate such market.



The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs need a comprehensive and thorough knowledge of the Chinese regulations for adverse drug reaction reporting and monitoring. The regulations on adverse drug reaction reporting and monitoring between China and US-EU are different. Moreover, the cultural difference between China and Western countries as well as the language barriers will increase the challenge faced by overseas and multinational pharmaceutical manufacturers and producers.

Chinese guidebook for Adverse Drug Reaction Reporting and Monitoring Regulations (2014) is an essential resource for overseas and multinational pharmaceutical manufacturers and producers to handle an adverse drug reaction reporting smoothly in China, which provides a detailed guidance of comprehensive and thorough knowledge of the Chinese adverse drug reaction reporting and monitoring regulations.


For more information visit http://www.researchandmarkets.com/research/3vqhjh/chinese_guidebook.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To TMCnet.com's Homepage ]